PureTech Health plc Annual Report - How They Did This Year

I’ve put together this guide to help you understand PureTech Health’s performance. Instead of digging through hundreds of pages of dense filings, I’ve broken down the key takeaways so you can decide if this company fits your investment goals.

1. What does this company do?

PureTech Health acts as a "biotech incubator." Instead of focusing on one or two drugs, they identify new biological ideas to build and spin off independent companies, which they call "Founded Entities." This strategy spreads risk across a diverse pipeline. If one project fails, others can still succeed. PureTech keeps a stake in these companies, aiming to make money when they grow, get licensed, or are sold.

2. Financial performance and health

Because they spin off companies, their income is unpredictable. They don't make money from regular product sales. Instead, they earn money when their smaller companies hit clinical goals, sign deals, or get bought.

The reality check: The company has never made a consistent profit from its drug programs. They spend cash to fund research and daily operations. This is a high-risk, growth-focused company. They have never paid a dividend, and they don't expect to pay one in the future.

• Audit Costs: The company spent $2.58 million on audit fees in 2025, down from $2.85 million in 2024. This reflects their effort to manage costs while meeting the strict reporting standards required for their dual-listing.

3. Recent Wins and Strategic Bets

PureTech’s portfolio is a mix of high-stakes bets. Here is what happened recently:

• The "Royalty" Cash Cow: They struck a deal with Royalty Pharma regarding KarXT, a schizophrenia treatment. The deal is worth up to $500 million. They received $100 million upfront, with $400 million more tied to the drug’s future success.
• The Gelesis Setback: PureTech invested heavily in Gelesis, which went bankrupt in 2023. This shows the incubator model's risk: when a spin-off fails, PureTech’s investment can be wiped out.
• Doubling Down on Seaport: PureTech is heavily invested in "Seaport Therapeutics," which focuses on brain-related medicines. They view Seaport as a major part of their business and hope to repeat past successes here.

4. Important Tax and Ownership Considerations

PureTech is a UK company, but the U.S. treats it as a domestic corporation for tax purposes.

• Tax Complexity: If they ever pay dividends, they count as U.S. income. Non-U.S. investors might face a 30% U.S. withholding tax, though tax treaties may lower this.
• Governance: As a "foreign private issuer" in the U.S., they follow UK corporate rules. They don't have to follow every rule U.S. companies do, such as holding meetings with only independent directors.

5. Major risks: What could go wrong?

• The "Never Profitable" Risk: They have a history of losses and may never turn a profit. Their success depends entirely on early-stage clinical trials.
• Cybersecurity: Cyberattacks could disrupt their business or steal sensitive data.
• Portfolio Volatility: As seen with Gelesis, spin-offs often fail. The failure of a key drug candidate can significantly hurt PureTech’s own value.

6. Future outlook

PureTech is in a "build and grow" phase. Their future depends on navigating tough drug pricing and regulatory rules. They must prove their medicines work and offer enough value to justify their costs to insurers and regulators.

Final Investor Takeaway: PureTech is a venture-capital-style play in the public markets. If you are looking for steady dividends or predictable quarterly earnings, this is likely not the right fit. However, if you are interested in a high-risk, high-reward model that bets on early-stage biotech innovation, their ability to monetize assets like KarXT demonstrates that they can successfully turn research into capital. Keep a close eye on their "Founded Entities"—the success of these individual companies is the primary driver of PureTech's stock value.